Algeta - Breast cancer Phase II
Feb 03rd 2010 - Edison Investment Research today published a report on Algeta entitled "Breast Cancer Phase II". In summary, the report says:
Enrolment has started in a Phase II trial of Alpharadin in bone metastases from breast cancer. The study should provide biomarker data that will support a Phase III study starting in 2011. Enrolment in the pivotal ALSYMPCA Phase III study in prostate cancer bone metastases is on track to complete this year, so the study should render results in late 2012. A Phase II study of Alpharadin in combination with docetaxel in prostate cancer should start later this year.
About the Author
Edison is Europe's leading independent investment research company. It has won industry recognition, with awards in both the UK and internationally. The team of 60 includes over 35 analysts supported by a department of supervisory analysts, editors and assistants.
...read more
